A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy.

CONTEXT Attainment of safe GH and IGF-1 levels is a central goal of acromegaly management. OBJECTIVE The aim of this study was to determine the extent to which reductions in GH and IGF-1 concentrations correlate with amelioration of radiological, metabolic, vascular, cardiac, and respiratory sequelae in a single unselected patient cohort. STUDY DESIGN This was a prospective, within-subject comparison in 30 patients with newly diagnosed acromegaly (15 women and 15 men: mean age, 54.3 years; range, 23-78 years) before and after 24 weeks of lanreotide Autogel (ATG) therapy. RESULTS Reductions in GH and IGF-1 concentrations and tumor volume were observed in all but 2 patients (median changes [Δ]: GH, -6.88 μg/L [interquartile range -16.78 to -3.32, P = .000001]; IGF-1, -1.95 × upper limit of normal [-3.06 to -1.12, P = .000002]; and pituitary tumor volume, -256 mm(3) [-558 to -72.5, P = .0002]). However, apnea/hypopnea index scores showed highly variable responses (P = .11), which were independent of ΔGH or ΔIGF-1, but moderately correlated with Δweight (R(2) = 0.42, P = .0001). Although systolic (P = .33) and diastolic (P = .76) blood pressure were unchanged, improvements in arterial stiffness (aortic pulse wave velocity, -0.4 m/s [-1.2 to +0.2, P = .046]) and endothelial function (flow mediated dilatation, +1.73% [-0.32 to +6.19, P = .0013]) were observed. Left ventricular mass index regressed in men (-11.8 g/cm(2) [-26.6 to -1.75], P = .019) but not in women (P = .98). Vascular and cardiac changes were independent of ΔGH or ΔIGF-1 and also showed considerable interindividual variation. Metabolic parameters were largely unchanged. CONCLUSIONS Presurgical ATG therapy lowers GH and IGF-1 concentrations, induces tumor shrinkage, and ameliorates/reverses cardiac, vascular, and sleep complications in many patients with acromegaly. However, responses vary considerably between individuals, and attainment of biochemical control cannot be assumed to equate to universal complication control.

[1]  V. Torri,et al.  Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly , 2012, PloS one.

[2]  A. Colao,et al.  Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. , 2011, European journal of endocrinology.

[3]  S. Skeie,et al.  Six‐month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure , 2011, Clinical endocrinology.

[4]  M. Rezai,et al.  Changes in arterial stiffness but not carotid intimal thickness in acromegaly. , 2011, The Journal of clinical endocrinology and metabolism.

[5]  P. Chanson,et al.  A consensus on criteria for cure of acromegaly. , 2010, The Journal of clinical endocrinology and metabolism.

[6]  P. Chanson,et al.  Endocrine aspects of obstructive sleep apnea. , 2010, The Journal of clinical endocrinology and metabolism.

[7]  A. Colao,et al.  Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. , 2009, The Journal of clinical endocrinology and metabolism.

[8]  P. Chanson,et al.  Guidelines for acromegaly management: an update. , 2009, The Journal of clinical endocrinology and metabolism.

[9]  W. Ricart,et al.  Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. , 2008, European journal of endocrinology.

[10]  M. Davi’,et al.  Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. , 2008, European journal of endocrinology.

[11]  J. Hald,et al.  Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. , 2008, The Journal of clinical endocrinology and metabolism.

[12]  N. Karavitaki,et al.  Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide , 2008, Clinical endocrinology.

[13]  T. Yoshimoto,et al.  Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. , 2008, Endocrine journal.

[14]  S. Melmed.  Medical progress: Acromegaly. , 2006, The New England journal of medicine.

[15]  H. Struijker‐Boudier,et al.  Expert consensus document on arterial stiffness: methodological issues and clinical applications. , 2006, European heart journal.

[16]  G. Tolis,et al.  Medical Treatment of Acromegaly: Comorbidities and Their Reversibility by Somatostatin Analogs , 2006, Neuroendocrinology.

[17]  D. Lüdecke,et al.  Transsphenoidal Microsurgery for Newly Diagnosed Acromegaly: A Personal View after More than 1,000 Operations , 2006, Neuroendocrinology.

[18]  M. Losa,et al.  Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. , 2006, Journal of neurosurgery.

[19]  S. Ball,et al.  Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. , 2005, The Journal of endocrinology.

[20]  P. Chanson,et al.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[21]  U. Plöckinger,et al.  Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study , 2005, Acta Neurochirurgica.

[22]  A. Blake,et al.  Somatostatin: a hormone for the heart? , 2005, Current vascular pharmacology.

[23]  R. Fahlbusch,et al.  The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. , 2005, European journal of endocrinology.

[24]  J. Bevan.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[25]  K. Mann,et al.  Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. , 2004, European journal of endocrinology.

[26]  G. Vitale,et al.  The heart: an end-organ of GH action. , 2004, European journal of endocrinology.

[27]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[28]  J. Cockcroft,et al.  The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. , 2003, The Journal of clinical endocrinology and metabolism.

[29]  Z. Šmahel,et al.  Cephalometric assessment of cranial abnormalities in patients with acromegaly. , 2003, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[30]  J. Neal,et al.  Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. , 2003, The Journal of clinical endocrinology and metabolism.

[31]  D. Bonaduce,et al.  Reversal of acromegalic cardiomyopathy in young but not in middle‐aged patients after 12 months of treatment with the depot long‐acting somatostatin analogue octreotide , 2003, Clinical endocrinology.

[32]  J. Hardy,et al.  Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly , 2003, Clinical endocrinology.

[33]  P M Stewart,et al.  Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. , 2002, The Journal of clinical endocrinology and metabolism.

[34]  P. Marzullo,et al.  Early vascular alterations in acromegaly. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  F. Di Salle,et al.  Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly , 2002, Clinical endocrinology.

[36]  W. Peh,et al.  Effect of Sandostatin® LAR® on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity , 2001, Clinical endocrinology.

[37]  K. Chihara,et al.  Bone metabolism and body composition in Japanese patients with active acromegaly , 2001, Clinical endocrinology.

[38]  D. Lüdecke,et al.  Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. , 2001, European journal of endocrinology.

[39]  P. Cappabianca,et al.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  Z. Ram,et al.  Transsphenoidal Surgery for Acromegaly: Endocrinological Follow-up of 98 Patients , 2001, Neurosurgery.

[41]  J. Jenkins,et al.  Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. , 2001, The Journal of clinical endocrinology and metabolism.

[42]  T. Young,et al.  Longitudinal study of moderate weight change and sleep-disordered breathing. , 2000, JAMA.

[43]  Stratton,et al.  Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience , 1999, Clinical endocrinology.

[44]  Davis,et al.  The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma , 1998, Clinical endocrinology.

[45]  P. Cappabianca,et al.  Effect of octreotide pretreatment on surgical outcome in acromegaly. , 1997, The Journal of clinical endocrinology and metabolism.

[46]  W. Heiss,et al.  Sleep apnoea in treated acromegaly: relative frequency and predisposing factors , 1996, Clinical endocrinology.

[47]  M. Hilton,et al.  Validation of British Thoracic Society guidelines for the diagnosis of the sleep apnoea/hypopnoea syndrome: can polysomnography be avoided? , 1995, Thorax.

[48]  C. Sullivan,et al.  Effect of Octreotide, a Somatostatin Analog, on Sleep Apnea in Patients with Acromegaly , 1994, Annals of Internal Medicine.

[49]  P. Marzullo,et al.  Growth hormone and the heart , 2001, Endocrine Updates.

[50]  J. Bollerslev,et al.  Body composition in active acromegaly during treatment with octreotide: a double‐blind, placebo‐controlled cross‐over study , 1994, Clinical endocrinology.

[51]  A. O’Sullivan,et al.  Body composition and energy expenditure in acromegaly. , 1994, The Journal of clinical endocrinology and metabolism.

[52]  A. Beckers,et al.  Presurgical Octreotide: treatment in acromegaly. , 1993, Metabolism: Clinical and Experimental.

[53]  A. Buda,et al.  Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. , 1992, Annals of internal medicine.

[54]  C. Sullivan,et al.  Sleep apnea in acromegaly. , 1991, Annals of internal medicine.

[55]  P. Chanson,et al.  Cardiovascular effects of the somatostatin analog octreotide in acromegaly. , 1990, Annals of internal medicine.

[56]  S. Gebarski,et al.  Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. , 1988, The Journal of clinical endocrinology and metabolism.

[57]  G. Mazziotti,et al.  Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review , 2009, Pituitary.

[58]  J. Vandenbroucke,et al.  Mortality in acromegaly: a metaanalysis. , 2008, The Journal of clinical endocrinology and metabolism.

[59]  L. Cavallo,et al.  Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. , 2006, The Journal of clinical endocrinology and metabolism.

[60]  P. Chanson,et al.  Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. , 2005, European journal of endocrinology.